Organizer(s): David M. Holtzman, Dora M. Kovacs and Cynthia A. LemereDate: March 24 - 29, 2008
Location: Keystone Resort, Keystone, CO, USA
Aggregation of the amyloid ß peptide and tau in the brain are key events in Alzheimer’s disease (AD). The understanding of the cell biological processes that lead to Aß formation is advancing rapidly. The cellular release, transport, and clearance of Aß and how Aß influences tau are just beginning to be understood. Studies of pathogenesis and treatment of AD with cellular and animal models are promising. Recent data in humans indicates that fluid and imaging biomarkers for both clinical and pre-clinical AD may be possible. Several pivotal issues that remain are: (1) to develop a full understanding of APP, A beta, and tau biology; (2) to be able to predict AD prior to cognitive decline; and (3) to develop effective methods to prevent and treat AD. The goal of this meeting will be to provide a state of the art update of the genetic, molecular, cell biological, and translational aspects of AD. Integration of current and novel bench and translational science in this area should lead to new ideas and collaborations.
Scholarship Deadline: November 26 2007
Discounted Abstract Deadline: November 26 2007
Abstract Deadline: December 26 2007
Discounted Registration Deadline: January 25 2008
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Merck & Co., Inc.